LESAKA TECHNOLOGIES INC 8-K

What Happened

• On May 12, 2026, Lesaka Technologies' Board approved an extension of Executive Chairman Ali Mazanderani's existing U.S. employment agreement to June 30, 2029 (previously Jan 31, 2028). He will continue to receive a $600,000 annual base salary and will remain ineligible for short‑term cash incentives or other bonus programs during the agreement term.
• The Board also approved principal terms of a separate South African employment arrangement with the company's subsidiary, Lesaka Technologies Proprietary Limited, expected to be effective July 1, 2026 and running through June 30, 2029. Under that arrangement Mr. Mazanderani would receive ZAR 5,000,000 per year and Lesaka SA would cover business travel costs up to ZAR 4,000,000 per financial year.
• The Company granted Mr. Mazanderani an option to purchase 1,000,000 shares of common stock at an exercise price of $5.00 per share. The grant is subject to shareholder approval at a meeting to be held no later than August 17, 2026. The options may be exercised only from April 1, 2029 to April 1, 2030 and vest only if he maintains continuous employment through April 1, 2028.

Key Details

• Board approval date: May 12, 2026; SA contract effective date: July 1, 2026 (term through June 30, 2029).
• U.S. base salary: $600,000 per year; South African base salary: ZAR 5,000,000 per year.
• Travel allowance (Lesaka SA): up to ZAR 4,000,000 per financial year.
• Option grant: 1,000,000 shares at $5.00 exercise price; shareholder approval required by Aug 17, 2026; exercise window Apr 1, 2029–Apr 1, 2030; vesting requires employment through Apr 1, 2028.

Why It Matters

• For investors, the filing outlines expanded compensation and a new local employment commitment for the company’s Executive Chairman, including a material travel allowance in South Africa and additional salary obligations.
• The 1,000,000‑share option grant represents potential future dilution if shareholders approve the award; exercise is years away and tied to continued employment, which limits near‑term dilution but creates a contingent equity claim.
• Shareholder approval is required by Aug 17, 2026, so investors who follow corporate governance or potential dilution events should note that upcoming vote.